Physician profile
Robert M Paschall
NPI 1164417499
$4,818.70
in general payments reported to CMS, 2019-2025
43 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $221 · 2021: $830 · 2022: $956 · 2023: $409 · 2024: $302 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582 · Education: $14.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.35 |
| Education | $14.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $709.94 | 2021-2025 | |
| Biogen, INC. | $550.09 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Acadia Pharmaceuticals INC | $533.00 | 2019-2025 | Nuplazid, Daybue |
| Amgen INC. | $326.24 | 2019-2025 | Uplizna |
| Ucb, INC. | $269.19 | 2019-2025 | Rystiggo, Fintepla |
| Lundbeck LLC | $246.46 | 2022-2023 | Vyepti |
| Livanova USA, INC. | $227.56 | 2019-2021 | |
| Lilly USA, LLC | $156.87 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Celgene Corporation | $156.12 | 2021-2025 | Zeposia |
| Horizon Therapeutics Plc | $145.83 | 2022 | |
| Eisai INC. | $127.64 | 2022-2025 | |
| Genzyme Corporation | $115.77 | 2019 | |
| Alexion Pharmaceuticals, INC. | $101.46 | 2019-2025 | Ultomiris |
| Abbott Laboratories | $88.99 | 2019-2025 | Infinity |
| Sumitomo Pharma America, INC. | $86.23 | 2023 | Aptiom |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Paschall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.